FDA approves Opdivo + Yervoy to treat hepatocellular cancer (liver cancer) .- BMS
Related news and insights
As part of its industry-wide review of accelerated approvals in oncology without confirmatory benefit, the FDA convened a public meeting of the Oncologic Drugs Advisory Committee to discuss impacted indications, including the U.S. indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Roche will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Hoffmann-La Roche Limited announced that Health Canada has granted market authorization for Tecentriq (atezolizumab for injection), in combination with Avastin (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.